Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Sponsor
GlaxoSmithKline
Study ID
NCT00516672
Phase
PHASE1
Status
Completed

Conditions

  • Carcinoma, Renal Cell

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • pazopanib — DRUG
    Pazopanib oral tablet
  • Lapatinib — DRUG
    Lapatinib oral tablet

Study Details

This is a two part phase I study in Japanese patients that will determine the safety, tolerability and pharmacokinetics of pazopanib monotherapy and of pazopanib in combination with lapatinib.

Key Dates

Start date
Sep 10, 2007
Status verified
Nov 2017
Primary completion
Aug 30, 2010
Completion
Oct 14, 2015

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    Pazopanib monotherapy or in combination with lapatinib

Primary Outcome Measure

Safety and tolerability [ Time Frame: before and after taking the study medications ]

Related Studies